Literature DB >> 15952087

Pentosidine plasma levels and relation with metabolic control in diabetic patients.

A Lapolla1, R Reitano, L Baccarin, G Sartore, M Plebani, D Fedele.   

Abstract

Levels of plasma pentosidine, a well-known AGE, were measured in type 2 diabetic patients in varying states of metabolic control to verify possible relationships between this parameter and traditional metabolic control parameters such as HbA1c and plasma glucose levels. At baseline, mean values of fasting plasma glucose, HbA1c and pentosidine were significantly higher in diabetic patients than those of controls, confirming patients' poor glycemic control. After ten months, patients with good metabolic control achieved showed near-normal HbA1c levels and reduced but not normalized pentosidine levels. Significant differences were found in the mean percentage decrease in the parameters. Regarding linear correlation, HbA1c levels only showed a positive relationship with plasma glucose values at baseline. Patients affected by chronic complications showed higher levels of pentosidine than those without complications. Thus, pentosidine plasma levels may be used to evaluate very long-term metabolic control in diabetic patients. In addition, a period of ten months of acceptable metabolic control is not enough to normalize pentosidine levels in diabetics, thus emphasizing the need for a longer period of improved metabolic control to reduce both this parameter and the burden of chronic diabetic complications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15952087     DOI: 10.1055/s-2005-861413

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  4 in total

1.  High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic control.

Authors:  T Neumann; S Lodes; B Kästner; S Franke; M Kiehntopf; T Lehmann; U A Müller; G Wolf; A Sämann
Journal:  Osteoporos Int       Date:  2014-03-06       Impact factor: 4.507

2.  The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.

Authors:  Joshua I Barzilay; Kathleen A Jablonski; Vivian Fonseca; Steven E Shoelson; Allison B Goldfine; Christopher Strauch; Vincent M Monnier
Journal:  Diabetes Care       Date:  2013-11-19       Impact factor: 19.112

3.  Prediction of Femoral Strength Based on Bone Density and Biochemical Markers in Elderly Men With Type 2 Diabetes Mellitus.

Authors:  Shaowei Jia; He Gong; Yingying Zhang; Hongmei Liu; Haipeng Cen; Rui Zhang; Yubo Fan
Journal:  Front Bioeng Biotechnol       Date:  2022-03-28

Review 4.  Advanced Glycation End Products in the Pathogenesis of Psoriasis.

Authors:  Anastasia Papagrigoraki; Martina Maurelli; Micol Del Giglio; Paolo Gisondi; Giampiero Girolomoni
Journal:  Int J Mol Sci       Date:  2017-11-20       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.